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OBJECTIVES The purpose of this prospective, randomized, double-blind, placebo-controlled study was to
assess the efficacy of preoperatively and postoperatively administered oral d,l sotalol in
preventing the occurrence of postoperative atrial fibrillation (AF).
BACKGROUND Atrial fibrillation is the most common arrhythmia following coronary artery bypass surgery
(CABG). Its etiology, prevention and treatment remain highly controversial. Furthermore, its
associated morbidity results in a prolongation of the length of hospital stay post-CABG.
METHODS A total of 85 patients, of which 73 were to undergo CABG and 12 CABG plus valvular
surgery (ejection fraction $28% and absence of clinical heart failure), were randomized to
receive either sotalol (40 patients; mean dose 5 190 6 43 mg/day) started 24 to 48 h before
open heart surgery and continued for four days postoperatively, or placebo (45 patients, mean
dose 5 176 6 32 mg/day).
RESULTS Atrial fibrillation occurred in a total of 22/85 (26%) patients. The incidence of postoperative
AF was significantly (p 5 0.008) lower in patients on sotalol (12.5%) as compared with
placebo (38%). Significant bradycardia/hypotension, necessitating drug withdrawal, occurred
in 2 of 40 (5%) patients on sotalol and none in the placebo group (p 5 0.2). None of the
patients on sotalol developed Torsade de pointes or sustained ventricular arrhythmias.
Postoperative mortality was not significantly different in sotalol versus placebo (0% vs. 2%,
p 5 1.0). Patients in the sotalol group had a nonsignificantly shorter length of hospital stay
as compared with placebo (7 6 2 days vs. 8 6 4 days; p 5 0.24).
CONCLUSIONS The administration of sotalol, in dosages ranging from 80 to 120 mg, was associated with a
significant decrease (67%) in postoperative AF in patients undergoing CABG without
appreciable side effects. Sotalol should be considered for the prevention of postoperative AF
in patients undergoing CABG in the absence of heart failure and significant left ventricular
dysfunction. (J Am Coll Cardiol 1999;34:334–9) © 1999 by the American College of
Cardiology
Atrial fibrillation (AF) represents the most common ar-
rhythmic complication of coronary artery bypass surgery
(CABG). It occurs in approximately 20% to 40% of patients
undergoing cardiac surgery (1–14). Furthermore, it usually
tends to occur within four days after the operation in most
patients, resulting in inappropriate tachycardia, increased
morbidity and significant prolongation of the length of
hospital stay. Although the etiology of postoperative AF is
incompletely understood, stimuli such as atrial ischemia
(13), preexisting structural changes related to age and
hypertension or mechanical damage, electrolyte imbalances
See page 340
and pericardial irritation are thought to play a role (14).
Studies on signal averaging of the P wave have suggested
that patients with prolonged signal averaged P-wave dura-
tion may be predisposed for the development of postoper-
ative AF (15). In the absence of a specific pathophysiologic
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target, no clear strategies have been proposed to reduce the
incidence of post-CABG AF. In this study we sought to
determine whether d,l sotalol could reduce the incidence of
post-CABG AF maintaining an acceptable safety profile.
METHODS
Patients. From February 1997 to August 1997, a total of
130 consecutive patients scheduled to undergo CABG were
screened. Of these, 85 patients (55 male, 30 female; mean
age 65 6 11 years) were randomized to receive either oral d,l
sotalol or placebo. Of these 85 patients, 73 were scheduled
to undergo CABG, and 12 patients were to receive CABG
with concomitant valvular surgery. The remaining patients
either did not satisfy the entry criteria or refused to
participate in the study. For all patients, an evaluation of left
ventricular myocardial function by echocardiography, left
ventricular angiography or radionuclide scan had been
obtained in the preceding two months. Exclusion criteria
included emergent open heart surgery; a prior history of AF
or atrial flutter; a left ventricular ejection fraction (LVEF)
, 28% (16) or clinically active congestive heart failure;
first-degree or higher degrees of atrioventricular (AV) block;
QTc (.450 ms); impaired renal function (serum creatinine
.2 mg/dl); chronic obstructive pulmonary disease; and
current use of antiarrhythmic drugs. Of the 85 patients
enrolled in the study, 20% had an LVEF of 30% to 40%,
42.5% of patients between 40% to 50%, and 37.5% of
patients above 50%. Medication was started 24 to 48 h
before scheduled surgery.
The study was designed as a two-center, double-blind,
randomized, placebo-controlled trial and was approved by
the human research committees of both institutions. This
study was not funded by a pharmaceutical company nor was
a pharmaceutical company involved in its formulation or
execution. The study was primarily supported by intramural
divisional funds.
Randomization and double-blind period. The patients
were enrolled in a registry by the hospital central pharmacy
of each institution, which randomized the patients in a
double-blind fashion and dispensed the medication and
placebo pills for all patients starting 24 to 48 h before
surgery and continued for up to four days postsurgery. In all
patients, the study medication was discontinued after the
fourth postoperative day. The placebo (mean dose 5 176 6
32 mg/day) was administered in identical fashion using,
respectively, two pills instead of the 80-mg and 120-mg
dose of sotalol. The study medication was started in-
hospital on the telemetry floor as 80 mg p.o. b.i.d., and
advanced up to 120 mg p.o. b.i.d., if there was no brady-
cardia defined as a rate of #40 beats/min, congestive heart
failure and QTc prolongation of .500 ms. The study
medication was discontinued if the QTc was .500 ms. All
other drugs were continued unchanged except beta-
adrenergic blocking agents, the dose of which was halved on
the day of the start of study medication if the dose of
beta-blocker was $200 mg/day of metoprolol or its equiv-
alent. Only two patients were on dosages above 200 mg/day,
and their dosage of beta-blocker was halved. The dose of
beta-blocker (metoprolol or atenolol) ranged from 25 to
100 mg/day in the placebo group and 25 to 50 mg/day in
the sotalol group. The postoperative dose of sotalol was not
changed. Sixty-five percent of the patients were on a total
dose of sotalol of 160 mg/day and the remaining 35% were
on 240 mg/day. The mean dose of sotalol was 190 6
43 mg/day. There was no significant difference (p 5 0.1) in
the total daily placebo and sotalol dose.
This study design was devised to avoid the occurrence of
beta-blocker withdrawal and assess the feasibility and effec-
tiveness of a strategy where sotalol is utilized in parallel with
prior beta-blocker regimen to minimize untoward effects of
this drug combination.
All patients were placed on cardiopulmonary bypass.
Seventy-three patients (86%) underwent CABG, and the
remaining 12 patients (14%) underwent CABG and con-
comitant valvular surgery. Myocardial protection was pro-
vided in all patients utilizing cold cardioplegia and topical
hypothermia. Immediate postoperative administration of
study medication was done by nasogastric tube.
All patients were monitored continuously with electro-
cardiographic (ECG) telemetry equipment, and their 24-h
report was reviewed by a study physician or study nurse
coordinator every day for any episode of AF. The end point
of the study was the occurrence of AF lasting more than or
equal to 30 min or for any length of time requiring
intervention due to symptoms (chest pain) or hemodynamic
compromise (hypotension, heart failure) or the completion
of four days of postoperative therapy. The study medication
was withheld if bradycardia resulting in hypotension oc-
curred. Both QT and QTc were monitored daily.
Follow-up. All patients were followed for the duration of
their hospital stay from the day of surgery. For placebo
group, mean 5 8 6 4 days, range 5 1 to 29 days; sotalol
group, mean 5 7 6 2 days, range 5 1 to 15 days.
Statistical analysis. All statistical analyses were completed
utilizing the SAS software package (Cary, North Carolina).
Clinical and hemodynamic variables including age, gender,
ejection fraction, presence of bundle branch block, time of
cardiopulmonary bypass (pump time), number of coronary
grafts, valvular surgery, the use of beta-blockers and the use
of sotalol versus placebo for the occurrence of postoperative
AF were tested using chi-square analysis, Fisher exact test
Abbreviations and Acronyms
AF 5 atrial fibrillation
AV 5 atrioventricular
CABG 5 coronary artery bypass surgery
LVEF 5 left ventricular ejection fraction
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where appropriate, and t-testing. Subsequently, a Categor-
ical Data Analysis was performed using the incidence of
postoperative AF as the dependent variable, with age,
beta-blockers and sotalol as dependent variables. The spe-
cific SAS procedure used was PROC CATMOD. All
values are expressed as the mean 6 SD.
RESULTS
Effect of sotalol on postoperative AF. Of the 85 patients
enrolled in the study, 45 were randomized to receive placebo
and 40 to receive sotalol. Table 1 summarizes the charac-
teristics of the patients on sotalol and on placebo. There was
no significant difference in the male/female ratio, LVEF,
pump time, the number of coronary artery grafts or valvular
surgery.
A significant difference existed in the occurrence of AF in
patients in the placebo group as compared to those receiving
sotalol (Table 2), but the day of occurrence of AF between
the sotalol and placebo groups was not significantly differ-
ent. A total of 17 of 45 (38%) patients receiving placebo had
postoperative AF onset on days 3 6 2, whereas only 5 of 40
(12.5%) patients on sotalol (mean dose 5 190 6 43 mg/day)
had postoperative AF on days 2 6 1 (Table 2). This
difference was highly significant (p 5 0.008). The AF lasted
from 0.5 h to 72 h in the placebo group and was paroxysmal
in 9 of 17 (56%) patients, whereas AF lasted for 0.5 h to
75 h in the sotalol group and was paroxysmal in 3 of 5 (75%)
patients. The difference in the incidence of paroxysmal AF
was not statistically significant in the two groups (p 5 0.78).
The patients on placebo were older (69 6 10 vs. 61 6 10
years; p 5 0.001) and a higher proportion were on beta-
blockers (47% vs. 20%; p 5 0.01).
Figure 1 shows the Kaplan-Meier analysis of the percent-
age of patients free from AF on sotalol as compared with
placebo. The estimated percentage of patients free of AF
was 87.5% in the sotalol group and 49% in the placebo
group for up to 10 days post-CABG. On days 4 to 6, there
was also a significant difference in the arrhythmia-free
incidence in the sotalol versus the placebo group (88% vs.
68%; p 5 0.03). The initial ventricular response during AF
was not significantly different in patients on sotalol as
compared with placebo (146 6 21 vs. 143 6 39 beats/min).
Because age, beta-blockers and the use of sotalol were
highly significant in the chi-square analysis, we assessed the
influence of these variables on the occurrence of AF using
Categorical Data Analysis. In this analysis, the use of sotalol
was still significant (p 5 0.03) in decreasing the incidence of
AF over all ages (p 5 0.68) and regardless of the use of
beta-blockers (p 5 0.60).
Influence of beta-blocker therapy. Of 45 patients on
placebo, 21 (47%) were on beta-blockers (Table 3). Of
these, 8 (38%) developed AF, whereas 9 (37.5%) of the
patients not taking beta-blockers developed AF. Of the
patients on sotalol, 8 were on beta-blockers. Of these, 2
(25%) developed AF, whereas AF occurred in 3 of 32
patients (9%) not on beta-blockers. This difference was not
statistically significant (p 5 0.24). The dose of sotalol in
patients on beta-blockers versus those not on beta-blockers
was not significantly different (186 6 48 mg/day vs. 188 6
44 mg/day).
Effects on the QTc interval. The QT interval was mea-
sured before the administration of sotalol and 3.4 6 1 days
after sotalol administration to determine any type III effects
of sotalol. The QTc interval was significantly prolonged on
sotalol as compared to before sotalol administration (458 6
38 ms vs. 419 6 29 ms; p 5 0.0001). There was no
significant difference in the QTc in the placebo group, pre-
and postsurgery (418 6 33 ms vs. 437 6 30 ms; p 5 0.1).
Side effects of therapy. None of the patients on sotalol or
on placebo required mechanical cardiac assist for weaning
from extracorporeal bypass. Two patients (5%) developed
significant side effects necessitating discontinuation of so-
talol; there were none in the placebo group. One of these
patients developed bradycardia and junctional rhythm post-
operatively. Dual-chamber pacing was readily instituted via
epicardial temporary wires left in at the time of surgery. In
one other patient the medication was discontinued in the
surgical ICU because of postoperative hypotension. No
patient on sotalol had torsade de pointes or ventricular
tachycardia.
Mortality. There was one death in the placebo group (2%),
29 days postoperative, following a cerebrovascular accident.
No deaths occurred in the sotalol group.
Length of hospital stay. Patients who were on the sotalol
arm of the study had a shorter length of hospital stay as
compared with those on placebo (7 6 2 days vs. 8 6 4 days).




AF (no. of patients) 5 (12.5%) 17 (38%) 0.008
AF (postoperative days) 2 6 1 3 6 2 0.22




No. 45 40 —
Age (yrs) 69 1 10 61 1 10 0.001
M/F 28/17 27/13 0.61
EF 48 6 9 50 6 9 0.40
Pump time 136 6 52 142 6 68 0.68
Valvular surgery 8 4 0.39
No. of coronary grafts 3 6 1 3 6 1 0.94
Beta-blockers 21 (47%) 8 (20%) 0.01
No. of hospital days 8 6 4 7 6 2 0.24
M 5 male; F 5 female; EF 5 ejection fraction; AF 5 atrial fibrillation; No. 5
number.
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However, this difference was not statistically significant
(p 5 0.24).
DISCUSSION
The incidence of AF remains high in post-CABG (1–14)
patients and represents a significant clinical burden in terms
of associated morbidity and length of hospital stay. Risk
factors for post-CABG AF include advancing age, male
gender, hypertension, need for an intraoperative balloon
pump, postoperative pneumonia, ventilation for more than
24 h and return to the intensive care unit (14). Signal
averaging studies of the P wave (15) have suggested that
patients who develop postoperative AF may have a substrate
for AF. Currently, no strategy is universally accepted and
implemented either for its prevention or for its treatment.
Because of a continuous rise in the mean age of patients
with CABG, more patients are at risk for this complication
than in past years. Consequently, a growing need has arisen
for optimizing a preventive approach. In light of its clinical
consequences, any reduction in its incidence will likely
translate into reduced morbidity and length of stay. For
these reasons, a search for the optimal prophylaxis is of
utmost necessity.
Current study. We chose sotalol as a prophylactic agent for
the prevention of postoperative AF for the following rea-
sons: 1) it has a type III membrane effect in addition to its
beta-blocker function; and 2) in patients already on beta-
blockers preoperatively, it would be easy to switch to sotalol
and to discontinue the beta-blocker or continue the beta-
blocker at a reduced dosage without beta-blocker with-
drawal effects. In addition, this approach could prevent
inadvertent bradycardia and hypotension.
To our knowledge, this is the first study where patients
without a prior history of AF were randomized in a
double-blind, placebo-controlled fashion where the study
drug was administered orally 24 to 48 h before surgery. In
addition, we tested whether moderate dosages would be
effective in preventing postoperative AF without significant
side effects. Our findings suggest that the use of sotalol in
moderate dosages is associated with a significantly lower
incidence of postoperative AF without appreciable side
effects. Only 5% of our patients developed bradycardia,
which required discontinuation of the drug, and none of the
patients developed ventricular arrhythmias including Tor-
sade de pointes. Furthermore, the findings in this study
Figure 1. Kaplan-Meier analysis of the percentage of patients free of atrial fibrillation on sotalol as compared to placebo. The abscissa plots
the time in days, and the ordinate plots the percentage of patients free of AF.






No. 21 24 8 32
AF 8 (38%) 9 (37.5%) 2 (25%) 3 (9%)
Bb 5 beta-blockers; AF 5 atrial fibrillation.
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suggest that sotalol need not be continued beyond postop-
erative day 4 because most AF occurs within four days of
surgery.
This study also confirms the previous observations that
age is a potent predictor of postoperative AF. Our analysis,
however, showed that the benefit of sotalol was independent
of age; the mean age of the patients in the placebo group
was ,70 years.
It remains unclear whether the beneficial effect of sotalol
is related to its beta-blocking effect or the class III mem-
brane activity. Although this study was not designed to
address that question, our observations of a significant
increase in the QTc interval suggest that the beneficial
effects of sotalol noted in this report were partly related to its
type III effects. It is of interest that in this study, a larger
number of patients in the placebo group, despite being on
beta-blockers, had a higher incidence of AF as compared to
the sotalol group. Furthermore, there was no difference in
the incidence of AF in patients in the placebo group who
were on beta-blockers when compared with those who were
not on beta-blockers (38% vs. 37.5%). It is noteworthy that
beta-blockers were not withdrawn in the placebo or the
sotalol group; rather, the dose was halved in only two
patients who were on a high dose of beta-blockers. Similar
observations have been recently reported by Parikka et al.
(17), who found a 32% incidence of postoperative AF in
patients randomized to metoprolol. In addition, there seems
not to have been an additive beneficial effect to the use of
beta-blocker therapy in patients on sotalol because the
incidence of AF was not significantly different in the
patients on beta-blocker plus sotalol in contrast with pa-
tients on only sotalol. Thus, these observations lend further
support that the benefit noted in the sotalol group was at
least partly if not fully related to its type III membrane
activity.
Also, we found no significant difference in the mean
ventricular response during AF in patients on sotalol versus
placebo. This observation may be related to the high
adrenergic state postoperatively and the small number of
patients on sotalol having AF. However, it is possible that
increasing the dose of sotalol after developing AF may
provide beneficial effects in controlling the ventricular re-
sponse.
Previous studies. The use of beta-blockers to prevent
postoperative AF has been controversial. Whereas some
studies have shown a beneficial effect, other studies have
shown differing effects (17–22). Two meta-analyses (18,19)
have shown a preventive effect of beta-blockers for post-
CABG supraventricular tachycardia inclusive of AF. In
contrast, no beneficial effect was detected for verapamil and
digoxin.
There are few studies investigating the use of anti-
arrhythmic drugs in the prevention of postoperative atrial
arrhythmias. In a small pilot trial, intravenous procainamide
followed by oral procainamide, administered postopera-
tively, was shown to reduce the incidence of postoperative
AF (23), whereas the prophylactic uses of quinidine (24)
and propafenone (25) have not shown significant beneficial
effects. Conversely, intravenous amiodarone given in a
loading bolus (26) followed by an infusion for four days was
associated with a significant reduction in postoperative AF
as compared to placebo (5% vs. 21%; p , 0.05). A recent
study by Daoud et al. (27) examined the efficacy of oral
amiodarone given seven days before surgery and discontin-
ued on the day of hospital discharge. These investigators
found that amiodarone significantly reduced the incidence
of postoperative AF relative to placebo (23% vs. 42%; p 5
0.03). However, the major drawback of amiodarone is that
it has to be given several days before surgery, at least seven,
as was done in their study. Furthermore, amiodarone is
known to result in postoperative pulmonary complications
in patients undergoing open heart surgery (28).
The effects of sotalol in preventing postoperative AF have
been controversial (29–31). Sotalol has been evaluated in
two previous European studies, where its use resulted in a
reduced incidence of postoperative AF (29,30). However,
both of these studies were open-labelled, not placebo-
controlled, and the medications were started following open
heart surgery. In contrast, Suttrop et al. (31) showed no
beneficial effects when comparing the efficacy and safety of
low- and high-dose sotalol versus propranolol started after
surgery. The lack of benefit noted in their study may be
related to the use of sotalol after CABG and the inclusion
of supraventricular tachycardia. Furthermore, in the studies
discussed, it is not clear whether patients with a past history
of recurrent AF were included as well.
Sotalol-related side effects. There was a very low inci-
dence of sotalol-related side effects in this study including
significant bradycardia and ventricular tachycardia. The
reason for this is unclear although the following explana-
tions can be offered: 1) the high adrenergic state, and the use
of inotropes in the postoperative state, may have accounted
for an absence of significant bradycardia and bradycardia-
related torsade de pointes type of ventricular tachycardia; 2)
the dosages of sotalol utilized in this study were low.
Sixty-five percent of patients were on a total daily dose of
160 mg and the remaining were on a total daily dose of
240 mg. Side effects from sotalol, particularly the occurrence
of Torsade-type ventricular tachycardia, have been reported
at dosages above 360 mg/day (32); 3) most patients (80%)
had a well-preserved LVEF of $40%; 4) patients with renal
dysfunction were excluded from the study.
Also, in a recent study comparing low-dose sotalol (160
to 240 mg) to metoprolol, started postoperatively, Parikka et
al. (17) did not observe any significant bradycardia, torsade
de pointes or ventricular fibrillation in their patients on
sotalol. They also reported a significantly higher heart rate
postoperatively as compared with preoperatively in both the
sotalol and metoprolol groups.
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Study implications. Our study suggests that low-dose
sotalol is a highly effective drug in preventing post-CABG
AF. The use of sotalol was associated with a 67% reduction
in AF without significant side effects. Thus, the results of
the present study suggest that the prophylactic use of sotalol
should be considered in patients undergoing CABG who
have relatively well-preserved ventricular function, absence
of heart failure and absence of renal dysfunction. However,
a larger multicenter study may be needed to determine the
ideal patient selection, its influence on hospital length of
stay and cumulative side effects of the drug before its general
use. It may be possible in the future to stratify patients at
risk for AF. Prospective studies in high-risk patients will be
necessary to assess the optimal prophylaxis.
Reprint requests and correspondence: Dr. J. Anthony Gomes,
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